gracemor.blogg.se

1. TORRENT PHARMA VISTA DIVISION PRODUCT LIST REGISTRATION
2. TORRENT PHARMA VISTA DIVISION PRODUCT LIST TORRENT

Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information herein should be regarded as a resource only and should be used at one's own risk. Equitymaster is not an Investment Adviser. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company.

TORRENT PHARMA VISTA DIVISION PRODUCT LIST REGISTRATION

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. The company seeks to expand the market for prescription lozenges with new launches this year. J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News) Aug 13, 2021 The company reported a 73% YoY increase in revenue driven by an uptick in the hospital and pharmacy business. Apollo Hospitals' Shares Rally Over 5%, Hit Record-High on Strong Results (Views On News) Aug 16, 2021 These companies are likely to benefit the most from Covid-19 vaccines. 5 Indian Pharma Companies Riding the Vaccination Wave (Views On News) Sep 3, 2021

TORRENT PHARMA VISTA DIVISION PRODUCT LIST TORRENT

Read on for a complete analysis of TORRENT PHARMA's quarterly results. Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). TORRENT PHARMA Announces Quarterly Results (2QFY21) Net Profit Up 27.0% ( Quarterly Result Update) | Updated on Oct 27, 2020įor the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY).

Key takeaways from Torrent Pharma's March quarter results. Related Views On News Torrent Pharma Beats Expectations: Stock Gets a Boost (Views On News) May 19, 2021